BLSM
BlossomHill Therapeutics, Inc.
There isn't enough reported data to score BLSM yet.
BLSM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate BLSM's fundamentals.
BLSM PE Valuation
BLSM has no meaningful PE right now: it lost money over the past year.
BLSM Forward outlook
There aren't enough analyst estimates for BLSM to show an outlook.
BLSM Earnings Per Share
BLSM Quarterly Revenue
BLSM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$21M | -$9.6M |
BLSM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q1 2025 | — |
BLSM Net Leverage
BLSM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BLSM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
As of the close on Nov 12, 2026: $14.84.
BLSM PE vs Healthcare Sector
BLSM has no meaningful PE right now: it lost money over the past year.
BLSM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.0 | 7% below |
BLSM is in a downtrend: it's below all one of its weekly moving averages, and 7% below its 8-week average.
BLSM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $16.0 | $14.8 | -7.3% |
It's down 7.3% so far in 2026.